AAA
Affinity Asset Advisors Portfolio holdings
AUM
$676M
This Quarter Return
+10.2%
1 Year Return
+29.75%
3 Year Return
+452.89%
5 Year Return
–
10 Year Return
–
AUM
$260M
AUM Growth
+$260M
(+19%)
Cap. Flow
+$35.1M
Cap. Flow
% of AUM
13.49%
Top 10 Holdings %
Top 10 Hldgs %
49.44%
Holding
80
New
15
Increased
23
Reduced
13
Closed
6
Top Buys
| 1 |
Merck
MRK
|
$12.8M |
| 2 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
$8.05M |
| 3 |
Madrigal Pharmaceuticals
MDGL
|
$5.57M |
| 4 |
BridgeBio Pharma
BBIO
|
$5.31M |
| 5 |
Cytokinetics
CYTK
|
$4.71M |
Top Sells
| 1 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$5.46M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
$5.35M |
| 3 |
Establishment Labs
ESTA
|
$5.25M |
| 4 |
Rocket Pharmaceuticals
RCKT
|
$5.05M |
| 5 |
NARI
Inari Medical, Inc. Common Stock
NARI
|
$4.32M |
Sector Composition
| 1 | Healthcare | 92.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
KDNY
1
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $22.6M | 7.46% | 976,021 +157,986 | +19% | +$3.66M |
|
|
2
Madrigal Pharmaceuticals
MDGL
$9.76B
| $22.5M | 7.44% | 93,000 +23,000 | +33% | +$5.57M |
|
|
RXDX
3
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $16.1M | 5.31% | 150,000 +75,000 | +100% | +$8.05M |
|
|
4
Merck
MRK
$210B
| $12.8M | 4.21% | +120,000 | New | +$12.8M |
|
5
Viking Therapeutics
VKTX
$3.04B
| $10.4M | 3.42% | 622,249 +272,249 | +78% | +$4.53M |
|
|
CBAY
6
DELISTED
Cymabay Therapeutics
CBAY
| $9.44M | 3.12% | 1,083,118 -60,413 | -5% | -$527K |
|
|
CERE
7
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $9.27M | 3.06% | 380,000 +165,000 | +77% | +$4.02M |
|
|
VRNA
8
Verona Pharma
VRNA
$9.16B
| $9.09M | 3% | 452,821 +140,323 | +45% | +$2.82M |
|
9
Ventyx Biosciences
VTYX
$171M
| $8.71M | 2.87% | 260,008 +19,385 | +8% | +$649K |
|
|
10
Cytokinetics
CYTK
$4.23B
| $7.79M | 2.57% | 221,463 +133,862 | +153% | +$4.71M |
|
|
11
Establishment Labs
ESTA
$1.2B
| $7.67M | 2.53% | 113,224 -77,543 | -41% | -$5.25M |
|
12
Astria Therapeutics
ATXS
$349M
| $7.04M | 2.32% | 529,369 +56,887 | +12% | +$757K |
|
|
BLU
13
DELISTED
BELLUS Health Inc.
BLU
| $6.35M | 2.09% | 881,329 +307,651 | +54% | +$2.22M |
|
14
Arcellx
ACLX
$3.85B
| $6.25M | 2.06% | 202,834 -37,309 | -16% | -$1.15M |
|
|
15
BridgeBio Pharma
BBIO
$9.89B
| $5.31M | 1.75% | +320,000 | New | +$5.31M |
|
|
MORF
16
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $5.11M | 1.69% | 135,863 -145,058 | -52% | -$5.46M |
|
17
Kura Oncology
KURA
$686M
| $4.37M | 1.44% | 357,287 +88,540 | +33% | +$1.08M |
|
|
INZY
18
DELISTED
Inozyme Pharma
INZY
| $4.31M | 1.42% | 751,796 +251,796 | +50% | +$1.44M |
|
19
Ascendis Pharma
ASND
$11.8B
| $4.29M | 1.42% | 40,000 -30,997 | -44% | -$3.32M |
|
20
AstraZeneca
AZN
$248B
| $4.16M | 1.37% | 60,000 | – | – |
|
|
SGEN
21
DELISTED
Seagen Inc. Common Stock
SGEN
| $4.05M | 1.34% | 20,000 +15,000 | +300% | +$3.04M |
|
22
argenx
ARGX
$43.6B
| $4.01M | 1.32% | 10,750 +5,750 | +115% | +$2.14M |
|
23
Xenon Pharmaceuticals
XENE
$2.98B
| $3.22M | 1.06% | 90,000 +40,000 | +80% | +$1.43M |
|
24
89bio
ETNB
$1.34B
| $3.05M | 1.01% | +200,000 | New | +$3.05M |
|
|
CNTA
25
Centessa Pharmaceuticals
CNTA
$2.25B
| $2.63M | 0.87% | 684,127 +223,799 | +49% | +$862K |
|